Clinical Report: Is Daptomycin Still Relevant in Managing Enterococcus faecium Bacteremia?
Background
Enterococcus species are significant contributors to healthcare-associated infections, particularly in ICU settings, where they account for a notable percentage of bloodstream infections. The management of Enterococcus faecium bacteremia is critical due to its association with high mortality rates and the emergence of antibiotic resistance, necessitating careful consideration of treatment options.
Data Highlights
In a multicentric retrospective cohort study, 200 patients with Enterococcus faecium bacteremia were analyzed. The study found that treatment failure occurred in 35% of patients receiving daptomycin compared to 20% in those receiving alternative therapies. Additionally, 15% of patients developed daptomycin resistance during treatment. Pharmacokinetic analysis revealed that critically ill patients had daptomycin serum levels below the therapeutic range in 40% of cases. Combination therapy with beta-lactams was associated with a 25% reduction in mortality compared to monotherapy.
Key Findings
Daptomycin treatment was associated with a higher risk of treatment failure compared to alternative regimens.
Resistance may emerge during daptomycin treatment, particularly under subinhibitory exposure.
Pharmacokinetic changes in critically ill patients may lead to suboptimal daptomycin concentrations.
Combination therapy with beta-lactams has shown synergistic activity against E. faecium.
There is a significant cost difference between daptomycin plus ceftaroline and vancomycin.
Clinical Implications
Clinicians should exercise caution when considering daptomycin monotherapy for Enterococcus faecium infections, particularly in critically ill patients. The potential for resistance emergence and the unclear role of combination therapy necessitate further research to optimize treatment strategies.
Conclusion
The optimal treatment strategy for Enterococcus faecium bacteremia in critically ill patients remains to be determined.
Related Resources & Content
Luque Paz and Tattevin, Critical Care, 2025 -- Is Daptomycin Still Relevant in Managing Enterococcus faecium Bacteremia in ICU Settings?
Drugs - Real World Outcomes — Comparative Effectiveness of Ceftaroline Versus Daptomycin as Initial Treatments for Diabetic Foot Infections in Inpatients: A Retrospective Cohort Study within the U.S. Veterans Health Care System
Drugs - Real World Outcomes — Efficacy of Ceftaroline Fosamil in Managing Methicillin-Resistant Staphylococcus Aureus Bacteremia: Insights from a Real-World Comparative Outcomes Analysis
International Journal of Infectious Diseases — Successful eravacycline monotherapy for cefiderocol-resistant Acinetobacter baumannii bloodstream infection in a critically ill patient with concomitant Clostridioides difficile colitis
EUCAST Daptomycin Guidance
Daptomycin is associated with higher treatment failure rates than alternatives for Enterococcus faecium bloodstream infections in critically ill patients: a multicentric retrospective cohort | Critical Care | Springer Nature Link
